With an eye toward helping patients with chronic kidney disease (CKD) receive earlier interventions, Fresenius Medical Care North America (FMCNA) has made an investment in Biointellisense Inc., of Denver. Biointellisense is developing a medical grade data services platform for continuous health monitoring, predictive analytics and algorithmic clinical insights.